News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Biotage AB: Interim Report January - March 2012
April 26, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Biotage (STO:BIOTA): First quarter 2012 · Group net sales increased by 12 percent to 119.6 MSEK (107.2). At comparable exchange rates sales increased by 8 percent.
Twitter
LinkedIn
Facebook
Email
Print
Europe
MORE ON THIS TOPIC
Neuropsychiatric disorders
Draig Takes Flight With $140M Series A To Advance Neuropsych Drugs
June 18, 2025
·
2 min read
·
Tristan Manalac
Opinion
US Uncertainty Creates Clinical Trial Leadership Opportunity for Europe
June 16, 2025
·
6 min read
·
Craig Koch
Layoffs
The 5 Largest Biopharma Layoffs of Q1 2025: Updated
May 13, 2025
·
5 min read
·
Angela Gabriel
Europe
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission
April 16, 2025
·
2 min read
·
Tristan Manalac
